FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients

Completed

• Conditions: Vascular Stiffness
• Interventions: Other: CAVI and FGF-21

• Registration Number: NCT02704468
• Lead Sponsor: Bangkok Metropolitan Administration Medical College and Vajira Hospital

Brief Summary

Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness. The cardio-ankle vascular index (CAVI) is a new index of overall stiffness and can estimated the risk of atherosclerosis.

Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.

Detailed Description

A total of 90 participants who underwent renal transplant were included in the study. The following measures were done and laboratory data were collected. CAVI, Ecchocariogram, Homocysteine, Hs-CRP, Carotid IMT, FGF-21, Medication after renal transplantation, incidence of cardiovascular disease correlation between categorical data was done by using Pearson's correlation test and multiple regression analysis.

Study Timeline

• Study Start: 2016-01
• Study First Submitted: 2016-02-29
• Study First Submitted QC: 2016-03-05
• Study First Posted: 2016-03-10
• Status Verified: 2016-07
• Primary Completion: 2016-07
• Study Completion: 2016-07
• Last Update Submitted: 2016-07-18
• Last Update Posted: 2016-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• renal transplant patients patients for more than 1 month

Exclusion Criteria

• who had contraindication for CAVI
• current smoker
• eGFR <15 ml/min/173
• cardiac arrthymia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
CAVI and FGF-21	CAVI and FGF-21	renal transplant patients for more than 1 month measured FGF-21 and CAVI

Primary Outcome Measures

Name	Time	Method
association between CAVI and FGF-21 with arterial stiffness in renal transplant patients	1 month	cross sectional study

Secondary Outcome Measures

Name	Time	Method
association between Hs-CRP,Homocystein with CAVI	1 month	cross sectional study

Trial Locations

Locations (1)

Bangkok metropolitan administraiton of vajira hospital; 🇹🇭 Bangkok, Thailand